PAVmed Inc. — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
PAVmed reported Q3 2026 results: Lucid Diagnostics achieved full Medicare reimbursement for EsoGuard (began October 2026, record month 1,800+ tests, $1.2M Q3 revenue); Veris Health completed implantable monitor design freeze and initiated 90-day GLP animal study (early 2027 FDA 510(k) submission target); PortIO and Octeris in FDA pre-submission discussions. PAVmed Q3 operating expenses $6.8M, non-GAAP adjusted loss $(0.19)/share; cash position $8.9M (vs. $1.5M end-2025). As Lucid's largest shareholder, PAVmed benefits directly from Lucid's revenue growth.
Why this rating
Medicare reimbursement is transformational for Lucid and material to PAVmed (5–7M company). Lucid revenue accelerating; Veris GLP initiation validates pathway. Meaningful near-term inflection.
Tradability signal
NO TRADE
No trade: only ~$35k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $1.52 | +10 min · unknown $1.45 ▼ 4.61% | +30 min · unknown $1.49 ▼ 2.30% | +1 hr · unknown $1.47 ▼ 3.29% | +4 hrs · unknown $1.63 ▲ 7.24% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.